Surface Oncology, Inc. Banner Image

Surface Oncology, Inc.

  • Ticker SURF
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Surface Oncology, Inc. Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (viaMore targeting CD112R, also known as PVRIG (SRF813)) or depleting regulatory T cells (via targeting CCR8 (SRF114)). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
4.8 / 5.0 (131)

Surface Oncology, Inc. reports have an aggregate usefulness score of 4.8 based on 131 reviews.

Surface Oncology, Inc.

Most Recent Annual Report

Surface Oncology, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Surface Oncology, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!